Targeting aggregation in the development of therapeutics for the treatment of Huntington’s disease and other polyglutamine repeat diseases

Bibliography

• ZOGHBI HY, ORR HT: Glutamine repeats and neurodegeneration. Ann. Rev Neurosci. (2000) 23:217–247.
   PubMed Web of Science ®Google Scholar
• ••Exceptionally well-written comprehensivereview.
   Google Scholar
• ROSS CA: Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron (2002) 35(5):819–822.
   PubMed Web of Science ®Google Scholar
• •Good overview of polyglutamine diseases.
   Google Scholar
• DAVIES SW, TURMAINE M, COZENS BA etal.: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 90:537–548.
   Google Scholar
• DIFIGLIA M, SAPP E, CHASE KO et al:Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 277:1990–1993.
   PubMed Web of Science ®Google Scholar
• BATES GP, MANGIARINI L, DAVIES SW: Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathal (1998) 8:699–714.
   PubMedGoogle Scholar
• NAKAMURA K, JEONG SY, UCHIHARA T et al: SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum. Mal Genet. (2001) 10(14):1441–1448.
   PubMed Web of Science ®Google Scholar
• ZUCCATO C, CIAMMOLA A, RIGAMONTI D et al: Loss of Huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 293:493–498.
   PubMed Web of Science ®Google Scholar
• CATTANEO E, RIGAMONTI D, GOFFREDO D, ZUCCATO C, SQUITIERI F, SIPIONE S: Loss of normal huntingtin function: new developments in Huntington's disease research. Trend s Neurosci. (2001) 24:1–8.
   PubMedGoogle Scholar
• PENNEY JB Jr, VONSATTEL JP MACDONALD ME, GUSELLA JF, MYERS RH: CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neural (1997) 41:689–692.
   PubMedGoogle Scholar
• PAULSON H: Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold. Am. J. Hum. Genet. (1999) 64:339–345.
   PubMed Web of Science ®Google Scholar
• PAULSON H: Toward an understanding of polyglutamine neurodegeneration. Brain Patna (2000) 10:293–299.
   PubMedGoogle Scholar
• LUNKES A, LINDENBERG KS, BEN-HAIEM L et al.: Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mal Cell (2002) 10:259–269.
   PubMedGoogle Scholar
• WANKER EE: Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. Biol. Chem. (2000) 381:937–942.
   PubMed Web of Science ®Google Scholar
• MITSUI K, NAKAYAMA H, AKAGI T etal.: Purification of polyglutamine aggregates and identification of elongation factor-1a and heat shock protein 84 as aggregate-interacting proteins. j. Neurosci. (2002) 22(21):9267–9277.
   Google Scholar
• MUCHOWSKI PJ, NING K, D'SOUZA-SCHOREY C, FIELDS S: Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant Huntingtin fragment. Proc. Natl. Acad. Sd. USA (2002) 99:727–732.
   PubMed Web of Science ®Google Scholar
• GUTEKUNST CA, LI SH, YI H et al: Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. j. Neurosci. (1999) 19:2522–2534.
   PubMed Web of Science ®Google Scholar
• SCHILLING G, BECHER MW, SHARP AH et al.: Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of Huntingtin. Hum. Mal Genet. (1999) 8:397–407.
   PubMedGoogle Scholar
• MORTON AJ, LAGAN MA, SKEPPER JN, DUNNETT SB: Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation. Neurocyrol (2000) 29(9):679–702.
   Google Scholar
• CHEN S, FERRONE FA, WETZEL R: Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sd. USA (2002) 99:11884–11889.
   PubMed Web of Science ®Google Scholar
• MORLEY JF, BRIGNULL HR, WEYERS JJ, MORIMOTO RI: The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caertorbabditis elegans. Proc. Natl. Acad. Sci. USA (2002) 99:10417–10422.
   PubMed Web of Science ®Google Scholar
• KAZANTSEV A, PREISINGER E, DRANOVSKY A, GOLD GABER D, HOUSMAN D: Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Nati Acad. Sci. USA (1999) 96:11404–11409.
   PubMed Web of Science ®Google Scholar
• PERUTZ MF, JOHNSON T, SUZUKI M, FINCH JT: Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. USA (1994) 91:5355–5358.
   PubMed Web of Science ®Google Scholar
• •Seminal paper describing potential structure of polyglutamine repeats.
   Google Scholar
• GREEN H: Human genetic diseases due tocodon reiteration: relationship to an evolutionary mechanism. Cell (1993) 74:955–956.
   PubMed Web of Science ®Google Scholar
• BATES G, HARPER E JONES L: Huntington's Disease Ord edn). Oxford University Press, Oxford (2002).
   Google Scholar
• ••Particularly informative and comprehensivebook.
   Google Scholar
• YANG W DUNLAP JR, ANDREWS RB, WETZEL R: Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Md. Genet. (2002) 11(23):2905–2917.
   PubMedGoogle Scholar
• CHA JH: Transcriptional dysregulation in Huntington's disease. Trends Neurosci. (2000) 23:387–392.
   PubMed Web of Science ®Google Scholar
• ••Useful review of transcriptionaldysregulation in polyglutamine-repeat diseases.
   Google Scholar
• SAUDOU E FINKBEINER S, DEVYS D, GREENBERG ME: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 95:55–66.
   PubMedGoogle Scholar
• KLEMENT IA, SKINNER PJ, KAYTOR MD et al.: Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell (1998) 94:41–53.
   Google Scholar
• PEREZ MK, PAULSON HL, PENDSE SJ, SAIONZE SJ, BONINI NM, PITTMAN RN: Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. Cell. Biol. (1998) 143:1457–1470.
   PubMed Web of Science ®Google Scholar
• LUTHI-CARTER R, STRAND A, PETERS NL etal.: Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Md. Genet. (2000) 9:1259–1267.
   Google Scholar
• WYTTENBACH A, SWARTZ J, KITA H et al.: Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. (2001) 10:1829–1845.
   PubMed Web of Science ®Google Scholar
• ORR HT: Microarrays and polyglutamine disorders: reports from the Hereditary Disease Array Group. Hum. Md. Genet. (2002) 11:1909–1910.
   PubMedGoogle Scholar
• FERNANDEZ-FUNEZ P, NINO ROSALES ML, DE GOUYON B et al.: Identification of genes that modify ataxin-l-induced neurodegeneration. Nature (2000) 408:101–106.
   Google Scholar
• KAZEMI-ESFARJANI P, BENZER S: Genetic suppression of polyglutamine toxicity in Drosophila. Science (2000) 287:1837–1840.
   PubMed Web of Science ®Google Scholar
• CHEN S, BERTHELIER V, YANG W, WETZEL R: Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. I Mol. Biol. (2001) 311(1):173–182.
   Google Scholar
• HUANG H et al.: Amyloid formation by mutant Huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell. Md. Genet. (1998) 24:217–233.
   PubMedGoogle Scholar
• STEFFAN JS, KAZANTSEV A, SPASIC-BOSKOVIC O et al.: The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Li. USA (2000) 97:6763–6768.
   PubMed Web of Science ®Google Scholar
• BOUTELL JM, THOMAS P, NEAL JW et al.: Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Md. Genet. (1999)9:1647–1655.
   Google Scholar
• NUCIFORA FC Jr, SASAKI M, PETERS MF et al.: Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity. Sdence (2001) 291:2423–428.
   Google Scholar
• SHIMOHATA T, NAKAJIMA T, YAMADA M et al.: Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. (2000) 26:29–36.
   PubMed Web of Science ®Google Scholar
• SUHR ST, SENUT MC, WHITELEGGE JP, FAULL KF, CUIZON DB, GAGE FH: Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. Cell. Biol. (2001) 153:283–294.
   PubMed Web of Science ®Google Scholar
• DUNAH AW, JEONG H, GRIFFIN A et al.: Spl and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science (2002) 296:2238–2243.
   PubMed Web of Science ®Google Scholar
• LI SH, CHENG AL, ZHOU H et al.: Interaction of Huntington's disease protein with transcriptional activator Spl. Md. Cell. Biol. (2002) 22:277–1287.
   Google Scholar
• KEGEL KB, MELONI AR, YI Y et al.: Huntingtin is present in the nucleus, interacts within the transcriptional corepressor C-terminal binding protein, and represses transcription. I Biol. Chem. (2002) 277:2466–2476.
   Google Scholar
• STEFFAN JS, BODAI L, PALLOS J etal.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature (2001) 413:739–743.
   Google Scholar
• HUGHES RE, LO RS, DAVIS C et al.: Altered transcription in yeast expressing expanded polyglutamine. Proc. Nati Acad. Li. USA (2001) 98:13201–13206.
   PubMed Web of Science ®Google Scholar
• MCCAMPBELL A, TAYE AA, WHITTY L, PENNEY E, STEFFAN JS, FISCHBECK KS: Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc. Nati Acad. Sci. USA (2001) 98:15179–15184.
   PubMed Web of Science ®Google Scholar
• RICHON VM, SANDHOFF TW, RIFKIND RA, MARKS PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA (2000) 97:10014–10019.
   PubMed Web of Science ®Google Scholar
• KEENE CD, RODRIGUES CM, EICH T, CHHABRA MH, STEER CJ, LOW WC: Taurooursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc. Natl. Acad. Sci. USA (2002) 99:10671–10676.
   PubMed Web of Science ®Google Scholar
• GRUNEWALD T, BEAL MF: Bioenergetics in Huntington's disease. Ann. NY Acad. Sci. (1999) 893:203–213.
   PubMed Web of Science ®Google Scholar
• PANOV AV, GUTEKUNST CA, LEAVITT BR et al.: Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. (2002) 5:731–736.
   PubMed Web of Science ®Google Scholar
• LI SH et al.: Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. Hum. Ma. Genet. (2000) 9:2859–2867.
   PubMedGoogle Scholar
• CHEN M, LAM S, CHENG AL, LI XJ: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nat. Med. (2000) 6:797–801.
   PubMed Web of Science ®Google Scholar
• HUGHES RE, OLSEN JM: Therapeutic opportunities in polyglutamine disease. Nat. Med. (2001) 7:419–423.
   PubMed Web of Science ®Google Scholar
• ••Useful review of therapeutic options inpolyglutamine desease.
   Google Scholar
• KIEBURTZ K: Antiglutamate therapies in Huntington's disease. j Neural. Tranvia Suppl. (1999) 55:97–102.
   PubMedGoogle Scholar
• YAMAMOTO A, LUCAS JJ, HEN R: Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 101:57–66.
   PubMed Web of Science ®Google Scholar
• BERTHELIER V, HAMILTON JB, CHEN S, WETZEL R: A microtiter plate assay for polyglutamine aggregate extension. Anal. Biochem. (2001) 295:227–236.
   PubMedGoogle Scholar
• HEISER V, SCHERZINGER E, BOEDDRICH A et al.: Inhibition of Huntingtin fibrillogenesisi by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Nati Acad. Sci. USA (2000) 97:6739–6744.
   PubMed Web of Science ®Google Scholar
• IMBERT G, SAUDOU F, YVERT G et al.: Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAGIglutamine repeats. Nat. Genet. (1996) 14:237–238.
   PubMedGoogle Scholar
• LECERF JM, SHIRLEY TL, ZHU Q et al.: Human single-chain Fy intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Li. USA (2001) 98:4764–4769.
   PubMed Web of Science ®Google Scholar
• KHOSHNAN A, KO J, PATTERSON PH: Effects of intracellular expression of anti-Huntingtin antibodies of various specificities on mutant Huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA (2002) 99:1002–1007.
   PubMed Web of Science ®Google Scholar
• YEN L, STRITTMATTER SM, KALB RG: Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann. Neurol. (1999) 46(3):366–373.
   PubMedGoogle Scholar
• NELLEMANN C, ABELL K, NORREMAN A et al.: Inhibition of Huntington synthesis by antisense oligodeoxynucleotides. Ma. Cell. Neurosci. (2000) 16(4):313–323.
   PubMedGoogle Scholar
• BOADO RJ, KAZANTSEV A, APOSTOL BL, THOMPSON LM, PARDRIDGE WM: Antisense-mediated down-regulation of the human huntingtin gene. I Pharmacol. Exp. Ther. (2000) 295:239–243.
   PubMed Web of Science ®Google Scholar
• CAPLEN NJ, TAYLOR JP, STATHAM VS,TANAKA E FIRE A, MORGAN RA: Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum. Md. Genet. (2002) 11(2):175–184.
   PubMedGoogle Scholar
• XIA H, MAO Q, PAULSON HL, DAVIDSON BL: siRNA-mediated gene silencing in vitro and in vivo. Nature Biotechnol. (2002) 20(10):1006–1010.
   PubMed Web of Science ®Google Scholar
• WELLINGTON CL, SINGARAJA R, METZLER M etal.: Inhibiting caspase cleavage of Huntingtin reduces toxicity and aggregate formation in neuronal and non-neuronal cells. j Biol. Chem. (2000) 275:19831–19838.
   Google Scholar
• WANG GH, MITSUI K, KOTLIAROVA S etal.: Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. Neuroreport (1999) 10(12):2435–2438.
   Google Scholar
• KIM M, LI HS, LAFORET G et al.: Mutant Huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. j Neurosci. (1999) 19:964–973.
   PubMed Web of Science ®Google Scholar
• ONA VO, LI M, VONSATTEL JP et al.: Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature (1999) 399:263–267.
   PubMed Web of Science ®Google Scholar
• SANCHEZ I, XU CJ, JUO P, KAKIZAKA A, BLENIS J, YUAN J: Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron (1999) 22:623–633.
   PubMed Web of Science ®Google Scholar
• GERVAIS FG, SINGARAJA R, XANTHOUDAKIS S et al.: Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat. Cell Biol. (2002) 4:95–105.
   PubMedGoogle Scholar
• SMITH DL, PORTIER R, WOODMAN B etal.: Inhibition of polyglutamine aggregation in R6/2 brain slices - complex dose-response profiles. Neurobiol. Dis. (2001) 8:1017–1026.
   Google Scholar
• FERRANTE RJ, ANDREASSEN O, JENKINS BG etal.: Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. j Neurosci. (2000) 20:4389–4397.
   Google Scholar
• BOADO RJ, KAZANTSEV A, APOSTOL BL, THOMPSON LM, PARDRIDGE WM: Antisense-mediated down-regulation of the human huntingtin gene. j Pharmacol. Esp. Ther. (2000) 295(1):239–243.
   PubMed Web of Science ®Google Scholar
• JOLLY C, MORIMOTO RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. Natl. Cancer Inst. (2000) 92:1564–1572.
   Google Scholar
• MUCHOWSKI PJ: Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones? Neuron (2002) 35(1):9–12.
   PubMed Web of Science ®Google Scholar
• GARRIDO C, GURBUXANI S, RAVAGNAN L, KROEMER G: Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem. Biophys. Res. Commun. (2001) 286:433–442.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI Y, KUME A, LI M et al.: Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptors protein with expanded polyglutamine tract. j Biol. Chem. (2000) 275:8772–8778.
   PubMed Web of Science ®Google Scholar
• WARRICK JM, CHAN HY, GRAY-BOARD GL, CHAT Y, PAULSON HL, BONINI NM: Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. (1999) 23:425–428.
   PubMed Web of Science ®Google Scholar
• CHAI Y, KOPPENHAFER SL, BONINI NM, PAULSON HL: Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. j Neurosci. (1999) 19:10338–19347.
   PubMed Web of Science ®Google Scholar
• MUCHOWSKI PJ, SCHAFFAR G, SITTLER A, WANKER EE, HAYER-HARTL MK, HARTL FU: Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Nati Acad. Li. USA (2000) 997:7841–7846.
   Google Scholar
• SATYAL SH, SCHMIDT E, KITAGAWA K et al.: Polyglutamine aggregates alter protein folding homeostasis in Caerrorhabditis elegans. Proc. Nati Acad. Sci. USA (2000) 97:5750–5755.
   PubMed Web of Science ®Google Scholar
• JANA NR, TANAKA M, WANG G, NUKINA N: Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Ma. Genet. (2000) 9:2009–2018.
   PubMed Web of Science ®Google Scholar
• STENOIEN DL, CUMMINGS CJ, ADAMS HP et al.: Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1 and are suppressed by the HDJ-2 chaperone. Hum. Ma. Genet. (1999) 8:731–741.
   PubMed Web of Science ®Google Scholar
• BAILEY CK, ANDRIOLA IF, KAMPINGA HH, MERRY DE: Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum. Mol. Civet. (2002) 11:515–523.
   PubMed Web of Science ®Google Scholar
• WYTTENBACH A, SAUVAGEOT O, CARMICHAEL J, DIAZ-LATOUD C, ARRIGO A1 RUBINSZTEIN DC: Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by Huntingtin. Hum. Ma. Genet. (2002) 11:1137–1151.
   PubMed Web of Science ®Google Scholar
• ZHOU H, U SH, LI XJ: Chaperone suppression of cellular toxicity of Huntingtin is independent of polyglutamine aggregation. j. Biol. Chem. (2001) 276:48417–48424.
   PubMedGoogle Scholar
• CUMMINGS CJ, SUN Y, OPAL P et al.: Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum. Md. Genet. (2001) 10:1511–1518.
   PubMed Web of Science ®Google Scholar
• CHAN HY, WARRICK JM, GRAY-BOARD GL, PAULSON HL, BONINI NM: Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy, and modulation of protein solubility in Drosophila. Hum. Mol. Genet. (2000) 9:2811–2820.
   PubMed Web of Science ®Google Scholar
• CHUANG JZ, ZHOU H, ZHU M, LI SH, LI XJ, SUNG CH: Characterization of a brain-enriched chaperone, MRJ, that inhibits Huntingtin aggregation and toxicity independently. j. Biol. Chem. (2002) 277:19831–19838.
   PubMedGoogle Scholar
• SITTLER A, LURZ R, LUEDER G etal.:Geldanamycin activates a heat shock response and inhibits Huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. (2001) 10:1307–1315.
   Google Scholar
• RIMOLDI M, SERVADIOI A, ZIMARINO V: Analysis of heat shock transcription factor for suppression of polyglutamine toxicity. Brain Res. Bull. (2001) 56:353–362.
   PubMedGoogle Scholar
• KROBITSCH S, LINDQUIST S: Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. USA (2000) 97:1589–1594.
   PubMed Web of Science ®Google Scholar
• MERIIN AB, ZHANG X, HEX, NEWNAM GP, CHERNOFF YO, SHERMAN MY: Huntingtin toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnql. J Cell. Biol. (2002) 157:997–1004.
   PubMed Web of Science ®Google Scholar
• NAGAI Y, TUCKER T, REN H et al.: Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. j. Biol. Chem. (2000) 275:10437–10442.
   PubMed Web of Science ®Google Scholar
• KAZANTSEV A, WALKER HA, SLEPKO N etal.: A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. (2002) 30:367–376.
   Google Scholar
• LESORT M, CHUN W, TUCHOLSKI J, JOHNSON GV: Does tissue transglutaminase play a role in Huntington's disease? Neurochem. Int. (2002) 40:37–52.
   Google Scholar
• KARPUJ MV, GARREN H, SLUNT H et al.: Transglutaminase aggregates Huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Li. USA (1999) 96:7388-7393. ma KIM SY, JEITNER TM, STEINERT PM: Transglutaminases in disease. Neurochem. km (2002) 40:85–103.
   Google Scholar
• COOPER AJ, JEITNER TM, GENTILE V, BLASS JP: Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)n/Qn-expansion diseases? Neurochem. mt. (2002) 40:53–67.
   Google Scholar
• KARPUJ MV, BECHER MW, STEINMAN L: Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem. mt. (2002) 40:31–36.
   PubMed Web of Science ®Google Scholar
• CRISTOFARO T, AFFAITATI A, CARIELLO L, AVVEDIMENTO EV, VARRONE S: The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates. Biochem. Biophys. Res. Commun. (1999) 260:150–158.
   PubMedGoogle Scholar
• WYTTENBACH A, CARMICHAEL J, SWARTZ J et al.: Effects of heat shock, heat shock protein 40 (HDJ-2) and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Nail. Acad. Sci. USA (2000) 97:2898–2903.
   PubMed Web of Science ®Google Scholar
• LESORT M, LEE M, TUCHOLSKI J, JOHNSON GV: Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. j. Biol. Chem. (2003) 278(6):3825–3830.
   Google Scholar
• KARPUJ MV, BECHER MW, SPRINGER JE et al.: Prolonged survival and decreased abnormal movements in transgenic model of Huntington's disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. (2002) 8:143–149.
   PubMed Web of Science ®Google Scholar
• DEDEOGLU A, KUBILUS JK, JEITNER JM et al.: Therapeutic effects of cystamine in a murine model of Huntington's disease. j. Neurosci. (2002). In Press.
   Google Scholar
• CHAT Y, KOPPENHAFER SL, SHOESMITH SJ, PEREZ MK, PAULSON HL: Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCAa3/ MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. (1999) 8:673–682.
   PubMed Web of Science ®Google Scholar
• CUMMINGS CJ, MANCINI MA, ANTALFFY B, DEFRANCO DB, ORR HT, ZOGHBI HY: Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCAL Nat. Genet. (1998) 19:148–154.
   PubMedGoogle Scholar
• STENOIEN DL, MIELKE M, MANCINI MA: Intranuclear ataxinl inclusions contain both fast- and slow-exchanging components. Nat. Cell Biol. (2002) 4(10):806–810.
   PubMedGoogle Scholar
• WAELTER S, BOEDDRICH A, LURZ R et al.: Accumulation of mutant Huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Ma. Biol. Cell (2001) 12:1393–1407.
   PubMed Web of Science ®Google Scholar
• BENCE NF, SAMPAT RM, KOPITO RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science (2001) 292:1552–1555.
   PubMed Web of Science ®Google Scholar
• VERHOEF LG, LINDSTEN K, MASUCCI MK, DANTUMA NP: Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. (2002) 11(22):2689–2700.
   PubMed Web of Science ®Google Scholar
• CHAN HY, WARRICK JM, ANDRIOLA I, MERRY D, BONINI NM: Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. (2002) 11(23):2895–2904.
   PubMedGoogle Scholar
• MARTIN-APARICIO E, YAMAMOTO A, HERNANDEZ F, HEN R, AVILA J, III. LUCAS JJ: Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. j. Neurosci. (2001) 21:8772–8781.
   PubMedGoogle Scholar
• DING Q, LEWIS JJ, STRUM KM etal.: Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival. ..J. Biol. Chem. (2002) 277:13935–13942.
   Google Scholar
• LOVESTONE S, MCLOUGHLIN DM: Protein aggregates and dementia: is there a common toxicity? J. Neura Neuroswg. Psychiatry (2002) 72:152–161.
   PubMedGoogle Scholar
• MA J, WOLLMANN R, LINDQUIST S: Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science (2002) 298(5599):1781–1785.
   PubMed Web of Science ®Google Scholar
• HEEMSKERK J, TOBIN AJ, BAIN LJ: Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7— 8 April 2002, Washington, DC, USA. Trends Neurosci. (2002) 25(10):494–496.
   Google Scholar
• WATASE K, WEEBER EJ, XU B etal.: A long CAG repeat in the mouse Scal locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron (2002) 34:905–919.
   Google Scholar
• SKINNER PJ, VIERRA-GREEN CA, EMAMIAN E, ZOGHBI HY, ORR HT: Amino acids in a region of ataxin-1 outside the polyglutamine tract influence the course of disease in SCA1 transgenic mice. Neural Mal. Med. (2002) 1:33–42.
   PubMedGoogle Scholar
• KUEMMERLE S, GUTEKUNST CA, KLEIN AM et al: Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann. Neural (1999) 46:842–849.
   PubMed Web of Science ®Google Scholar
• TAYLOR JP, HARDY J, FISCHBECK KH: Toxic proteins in neurodegenerative disease. Science (2002) 296:1991–1994.
   PubMed Web of Science ®Google Scholar
• FERRANTE RJ, ANDREASSEN OA, DEDEOGLU A et al: Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. j. Neurosci. (2002) 22:1592–1599.
   PubMed Web of Science ®Google Scholar
• THE HUNTINGTON'S DISEASE COLLABORATIVE RESEARCH GROUP: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology (2001) 57:397–404.
   Google Scholar
• •Seminal paper describing cloning of the HD gene.
   Google Scholar
• HEISER V, ENGEMANN S, BROCKER W et al: Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl. Acad. Sci. USA (2002). In Press.
   Google Scholar
• SANCHEZ I, MAHLKE C, YUAN J: Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature (2003) 421:373–379.
   PubMed Web of Science ®Google Scholar